Release Date: 19-Sep-2024
JSKN-003 is an innovative bispecific antibody-drug conjugate (ADC) developed by Alphamab Oncology, targeting HER2-expressing solid tumors. Leveraging a proprietary glycan-specific conjugation platform, JSKN-003 represents a significant advancement in ADC technology, aiming to enhance therapeutic efficacy and safety profiles in cancer treatment.
This ADC utilizes a unique approach where the payloads are site-specifically linked to glycans on the Fc region of the antibody through enzyme catalysis and click chemistry. This meticulous engineering ensures a consistent drug-to-antibody ratio (DAR) and improves stability, making JSKN-003 a promising candidate for various HER2-positive cancers. Upon binding to the HER2 receptor, JSKN-003 induces receptor clustering, which facilitates extensive internalization of the JSKN-003-HER2 complex. This process leads to the release of the cytotoxic payload, which can kill tumor cells directly or generate a bystander effect, thereby affecting neighboring cells that may not express HER2.
Cancer Antibody Drug Conjugates Clinical Trials Insight: https://www.kuickresearch.com/ccformF.php?t=1726727004
What sets JSKN-003 apart from other ADCs is its ability to promote faster and more intense endocytosis, resulting in a more pronounced bystander effect in HER2-expressing tumors. Additionally, the improved serum stability of JSKN-003 ensures a wider therapeutic window, which is critical for maximizing efficacy while minimizing adverse effects. Preclinical studies indicate that JSKN-003 not only has a better safety profile but also demonstrates comparable tumor-killing activity to Enhertu in both high and low HER2 expression models, including patient-derived xenografts (PDX) and cell line-derived xenografts (CDX).
Currently, a Phase 3 clinical trial is underway in China, assessing the efficacy and safety of JSKN-003 in patients with recurrent or metastatic breast cancer who have previously failed first- or second-line chemotherapy. This trial is crucial in establishing JSKN-003’s role as a leading therapeutic option in the challenging landscape of HER2-positive breast cancer.
Furthermore, additional early-phase clinical trials are being conducted for various advanced solid tumors, reflecting the broad potential of JSKN-003 in treating different cancer types. With its innovative design and promising early results, JSKN-003 stands poised to make a significant impact in the treatment of HER2-expressing malignancies, potentially offering hope to patients who have exhausted existing treatment options. JSKN003, JSKN-003, JSKN-003 clinical trials, JSKN-003 fda approval, JSKN-003 cancer, JSKN-003 research, JSKN-003 development, JSKN-003 immunotherapy, JSKN-003 Alphamab, JSKN-003 adc, JSKN-003 antibody drug conjugate, JSKN-003 designation, JSKN-003 fda designation, JSKN-003 nmpa, JSKN-003 HER2, JSKN-003 bispecific ADC